Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609

Watchlist Manager
Shanghai HeartCare Medical Technology Corp Ltd Logo
Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
Watchlist
Price: 21.4 HKD 1.66% Market Closed
Market Cap: 831.1m HKD
Have any thoughts about
Shanghai HeartCare Medical Technology Corp Ltd?
Write Note

Shanghai HeartCare Medical Technology Corp Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai HeartCare Medical Technology Corp Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Additional Paid In Capital
ÂĄ724m
CAGR 3-Years
66%
CAGR 5-Years
46%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Additional Paid In Capital
ÂĄ2B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
40%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Additional Paid In Capital
ÂĄ6.9B
CAGR 3-Years
-5%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
J
Jafron Biomedical Co Ltd
SZSE:300529
Additional Paid In Capital
ÂĄ711.8m
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Additional Paid In Capital
ÂĄ13.9B
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai HeartCare Medical Technology Corp Ltd
Glance View

Market Cap
831.1m HKD
Industry
Health Care

Shanghai Heartcare Medical Technology Corp. Ltd. engages in the research, development, manufacture, and sale of neuro-interventional medical devices. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-08-20. The firm's product portfolio includes both neuro-interventional and cardiac medical devices, and its main products are CaptorTM thrombectomy device (Captor) and left atrial appendage occluder. The firm's product portfolio extends from the treatment and prevention of ischemic stroke, including acute ischemic stroke and intracranial stenosis to the treatment of hemorrhagic stroke. The firm's other products include the balloon guiding catheter, the ExtraFlex distal access catheter and SupSelek microcatheter. The firm distributes its products within the domestic market.

Intrinsic Value
34.56 HKD
Undervaluation 38%
Intrinsic Value
Price

See Also

Back to Top